|
Market Closed -
Nasdaq
02:30:00 24/01/2026 am IST
|
5-day change
|
1st Jan Change
|
|
56.21 USD
|
-1.70%
|
 |
+2.97%
|
-5.42%
|
|
20/01 |
Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy From Hold, Adjusts Price Target to $98 From $84
|
MT
| |
20/01 |
Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…
|  | |
14/01 |
BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says
|
MT
| |
22/12 |
Truist Securities Lifts BioMarin Pharmaceutical Price Target to $100 From $80, Maintains Buy Rating
|
MT
| |
19/12 |
Top Midday Gainers
|
MT
| |
03/12 |
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform From Outperform, Adjusts PT to $60 From $82
|
MT
| |
07/11 |
BioMarin Pharmaceutical Shares Drop After Downgrade From Stifel
|
MT
| |
06/11 |
Stifel Downgrades BioMarin Pharmaceutical to Hold From Buy, Adjusts Price Target to $61 From $73
|
MT
| |
29/25/29 |
Fda accepts Biomarin's Palynziq supplemental bla for priority review to expand use to adolescents aged 12-17 with phenylketonuria
|
RE
| |
28/25/28 |
Truist Lowers Price Target on BioMarin Pharmaceutical to $80 From $90, Keeps Buy Rating
|
MT
| |
28/25/28 |
RBC Cuts Price Target on BioMarin Pharmaceutical to $66 From $70, Keeps Sector Perform Rating
|
MT
| |
28/25/28 |
Morgan Stanley Trims Price Target on BioMarin Pharmaceutical to $98 From $104, Keeps Overweight Rating
|
MT
| |
28/25/28 |
Analyst recommendations: Confluent, Crowdstrike Holdings, Fox Corporation, Oracle, Apple…
| | |
08/25/08 |
HC Wainwright Initiates Coverage on BioMarin Pharmaceutical With Neutral Rating, $60 Price Target
|
MT
| |
05/25/05 |
UBS Adjusts Price Target on BioMarin Pharmaceutical to $114 From $113, Maintains Buy Rating
|
MT
| |
05/25/05 |
Morgan Stanley Raises Price Target on BioMarin Pharmaceutical to $104 From $96, Keeps Overweight Rating
|
MT
| |
05/25/05 |
BioMarin Pharma Q2 revenue beats estimates
|
RE
| |
25/25/25 |
Analyst recommendations: Block, Lucid, Celsius, Dun & Bradstreet, Sentinelone...
| | |
24/25/24 |
Oppenheimer Upgrades BioMarin Pharmaceutical to Outperform From Market Perform, Price Target is $98
|
MT
| |
20/25/20 |
UBS Adjusts Price Target on BioMarin Pharmaceutical to $113 From $109, Maintains Buy Rating
|
MT
| |
03/25/03 |
BofA Adjusts Price Target on BioMarin Pharmaceutical to $99 From $100
|
MT
| |
25/24/25 |
RBC Cuts Price Target on BioMarin Pharmaceutical to $70 From $80, Keeps Sector Perform Rating
|
MT
| |
15/24/15 |
Wolfe Research Initiates BioMarin Pharmaceutical at Outperform With $95 Price Target
|
MT
| |
30/24/30 |
UBS Adjusts Price Target on BioMarin Pharmaceutical to $106 From $104, Maintains Buy Rating
|
MT
| |
30/24/30 |
William Blair Downgrades BioMarin Pharmaceutical to Market Perform From Outperform
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
